ArticleNature2022
Potentiating adoptive cell therapy using synthetic IL-9 receptors.
Erratum issuedOpen access · hybridAbstract read
In one paragraph
Article in Nature, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 73 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
73citing papers in PubMed, 1 pooled it
10.5field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
73 citing papers in PubMed, 1 synthesis or guideline pooled it, 109 citations in OpenAlex.
- Strategies and mechanisms for the enhancement of chimeric antigen receptor T-cell functions.Science China. Life sciences · 2026Pooled it
- Cell-based cancer immunotherapy: milestones, mechanistic insights, and emerging therapeutic directions.Acta pharmacologica Sinica · 2026Review
- A guide to CAR T cell therapies: development, current status and future prospects.Nature reviews. Immunology · 2026Review
- Engineering a Transmembrane Receptor for Coacervate-Based Artificial Cells.Journal of the American Chemical Society · 2026Article
- Rewiring STAT signaling from the cell surface with Trikine immunotherapeutics.Science (New York, N.Y.) · 2026Article
- Optimizing next-generation CAR-macrophages against solid tumors: challenges and potential strategies.Journal of hematology & oncology · 2026Review
- Microenvironmental regulation of solid tumour resistance to CAR T cell therapy.Nature reviews. Immunology · 2026Review
- Common gamma chain cytokines-driven optimization of chimeric antigen receptor T cells: Mechanistic insights and future directions.World journal of clinical oncology · 2026Review
- Antigen-IL-2 CAR-enhancer drives CAR-T fate and stemness, enhancing antitumor efficacy across models independent of IL-2Rα.Journal for immunotherapy of cancer · 2026Article
- Regulators of CD8Nature reviews. Immunology · 2026Review
- Dextran-based T-cell expansion nanoparticles for manufacturing CAR T cells with augmented efficacy.Nature communications · 2026Article
- IL-9 as a naturally orthogonal cytokine with optimal JAK/STAT signaling for engineered T cell therapy.Immunity · 2026Article
- Intrathecal CRISPR-edited allogeneic IL-13Rα2 CAR T Cells for recurrent high-grade Glioma: preclinical characterization and phase I trial.Nature communications · 2026Article
- Review
- In vivo CAR-T cell engineering: concept, research progress, potential challenges and enhancement strategies.Experimental hematology & oncology · 2025Review
- CAR-T cells in solid tumors: Challenges and breakthroughs.Cell reports. Medicine · 2025Review
- CellNavi predicts genes directing cellular transitions by learning a gene graph-enhanced cell state manifold.Nature cell biology · 2025Article
- CAR T cell persistence in cancer.Trends in cancer · 2025Review
- Article
- Regulatory T cell therapy for Graft-versus-Host Disease.Bone marrow transplantation · 2025Review
13 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on by
- Erratum issued
Authors and funding
23 authors at 6 institutions in 1 country.
Anusha Kalbasi *Department of Radiation Oncology, David Geffen School of Medicine and Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA, USA. anushakalbasi@mednet.ucla.edu.ORCID http://orcid.org/0000-0001-8692-1457
Mikko Siurala *Parker Institute for Cancer Immunotherapy, San Francisco, CA, USA.
Leon L Su *Departments of Molecular and Cellular Physiology and Structural Biology, Stanford University School of Medicine, Stanford, CA, USA.ORCID http://orcid.org/0000-0001-7654-9997
Mito TariveranmoshabadDepartment of Radiation Oncology, David Geffen School of Medicine and Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA, USA.
Lora K PictonDepartments of Molecular and Cellular Physiology and Structural Biology, Stanford University School of Medicine, Stanford, CA, USA.ORCID http://orcid.org/0000-0002-0482-5187
Pranali RavikumarCenter for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Peng LiLaboratory of Molecular Immunology and the Immunology Center, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-4721-5936
Jian-Xin LinLaboratory of Molecular Immunology and the Immunology Center, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.
Helena Escuin-OrdinasDivision of Hematology/Oncology, Department of Medicine, David Geffen School of Medicine and Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA, USA.
Tong DaCenter for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Sarah V KremerDepartment of Radiation Oncology, David Geffen School of Medicine and Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA, USA.ORCID http://orcid.org/0000-0001-9563-4986
Amy L SunDivision of Hematology/Oncology, Department of Medicine, David Geffen School of Medicine and Jonsson Comprehensive Cancer Center, University of California, Los Angeles, Los Angeles, CA, USA.
Sofia CastelliCenter for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0001-6185-2838
Sangya AgarwalCenter for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0003-4272-515X
John SchollerCenter for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Decheng SongCenter for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Philipp C RommelCenter for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0002-9790-4086
Enrico RadaelliPenn Vet Comparative Pathology Core, Department of Pathobiology, University of Pennsylvania, Philadelphia, PA, USA.ORCID http://orcid.org/0000-0002-2885-0221
Regina M YoungCenter for Cellular Immunotherapies, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA, USA.
Warren J LeonardLaboratory of Molecular Immunology and the Immunology Center, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA.ORCID http://orcid.org/0000-0002-5740-7448
Antoni RibasParker Institute for Cancer Immunotherapy, San Francisco, CA, USA. aribas@mednet.ucla.edu.ORCID http://orcid.org/0000-0003-3669-8458
Carl H JuneParker Institute for Cancer Immunotherapy, San Francisco, CA, USA. cjune@upenn.edu.ORCID http://orcid.org/0000-0003-0241-3557
K Christopher GarciaParker Institute for Cancer Immunotherapy, San Francisco, CA, USA. kcgarcia@stanford.edu.ORCID http://orcid.org/0000-0001-9273-0278
University of Pennsylvania · USUniversity of California, Los Angeles · USNational Institutes of Health · USParker Institute for Cancer Immunotherapy · USStanford University · USHoward Hughes Medical Institute · US
Funding
UNIVERSITY OF PENNSYLVANIA CAN CTR SUPPORT GRANTP30CA016520 · NCI · UNIVERSITY OF PENNSYLVANIA · PI Robert H. Vonderheide · 1985 to 2026
$222.3MWomen's CancersP30CA016042 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Samuel Wheeler French · 1985 to 2026
$134.5MIL-2 Family Cytokines and their Receptors-- Molecular Regulation via STATsZIAHL005402 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI LEONARD, WARREN J · 2009 to 2025
$26.8MIL-2 Family Cytokines and their Receptors-- Biology of the IL-2 systemZIAHL005401 · NHLBI · NATIONAL HEART, LUNG, AND BLOOD INSTITUTE · PI LEONARD, WARREN J · 2009 to 2025
$22.5MIMMUNOBIOLOGY OF NORMAL AND NEOPLASTIC LYMPHOCYTEST32CA009140 · NCI · UNIVERSITY OF PENNSYLVANIA · PI Malay Haldar, WARREN S PEAR · 1985 to 2026
$16.1MProject 3: Modeling and overcoming resistance to melanoma immunotherapyP01CA244118 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI MORICEAU, GATIEN P · 2020 to 2024
$12.8MNext Generation Cancer Immunotherapies to Defeat MelanomaR35CA197633 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI ANTONI RIBAS · 2015 to 2026
$10.4MProject 3U54CA244711 · NCI · UNIVERSITY OF PENNSYLVANIA · PI JUNE, CARL H. · 2019 to 2022
$7.1MStructure, function and engineering of immune cytokine receptor signalingR37AI051321 · NIAID · STANFORD UNIVERSITY · PI GARCIA, KENAN CHRISTOPHER · 2013 to 2022
$4.2MTargeting Radiation-Induced Myeloid Cells to Promote T cell Immunity in Undifferentiated Pleomorphic SarcomaK08CA245181 · NCI · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI KALBASI, ANUSHA · 2020 to 2025
$1.1MAperio VERSA Digital Slide Scanner, eSlide Manager Database, and Advanced Image Analysis SoftwareS10OD023465 · OD · UNIVERSITY OF PENNSYLVANIA · PI DURHAM, AMY CLEVELAND · 2018 to 2018
$329kHoward Hughes Medical InstituteNCI NIH HHS K08 CA245181NCI NIH HHS P01 CA244118NCI NIH HHS P30 CA016042NCI NIH HHS P30 CA016520NCI NIH HHS R35 CA197633NCI NIH HHS T32 CA009140NCI NIH HHS U54 CA244711NIAID NIH HHS R37 AI051321NIH HHS K08 5K08CA245181NIH HHS S10 OD023465NIH HHS T32 5T32CA009140
Abstract
Synthetic receptor signalling has the potential to endow adoptively transferred T cells with new functions that overcome major barriers in the treatment of solid tumours, including the need for conditioning chemotherapy
Indexed as
Cell- and Tissue-Based TherapyImmunotherapy, AdoptiveInterleukin Receptor Common gamma SubunitNeoplasmsReceptors, Interleukin-9Recombinant Fusion ProteinsT-LymphocytesAnimalsInterleukinsMelanomaMicePancreatic NeoplasmsSTAT Transcription FactorsInterleukin Receptor Common gamma SubunitInterleukinsReceptors, Interleukin-9Recombinant Fusion ProteinsSTAT Transcription Factors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.